Home > Publications database > Pre-Transplant Serum Leptin Levels and Relapse of Acute Myeloid Leukemia after Allogeneic Transplantation. > print

001     179137
005     20240229145534.0
024 7 _ |a 10.3390/ijms23042337
|2 doi
024 7 _ |a pmid:35216457
|2 pmid
024 7 _ |a pmc:PMC8879842
|2 pmc
024 7 _ |a 1422-0067
|2 ISSN
024 7 _ |a 1661-6596
|2 ISSN
024 7 _ |a altmetric:123701529
|2 altmetric
037 _ _ |a DKFZ-2022-00493
041 _ _ |a English
082 _ _ |a 540
100 1 _ |a Schwarzbich, Mark-Alexander
|b 0
245 _ _ |a Pre-Transplant Serum Leptin Levels and Relapse of Acute Myeloid Leukemia after Allogeneic Transplantation.
260 _ _ |a Basel
|c 2022
|b Molecular Diversity Preservation International
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1647611168_25816
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Weight loss and metabolic activity influence outcome after allogeneic stem cell transplantation (alloSCT). This study evaluates pre-conditioning Leptin, a peptide hormone involved in metabolism and immune homeostasis, as a prognostic factor for survival, relapse and non-relapse mortality (NRM) following alloSCT. Leptin serum levels prior to conditioning were determined in a cohort of patients transplanted for various hematologic malignancies (n = 524) and correlated retrospectively with clinical outcome. Findings related to patients with acute leukemia (AL) from this sample were validated in an independent cohort. Low pre-conditioning serum Leptin was an independent prognostic marker for increased risk of relapse (but not of NRM and overall mortality) following alloSCT for AL of intermediate and advanced stage (beyond first complete remission). Multivariate analysis revealed a hazard ratio (HR) for relapse of 0.75 per log2 increase (0.59-0.96, p = 0.020). This effect was similar in an independent validation cohort. Pre-conditioning serum Leptin was validated as a prognostic marker for early relapse by fitting the multivariate Cox model to the validation data. Pre-conditioning serum Leptin levels may serve as an independent prognostic marker for relapse following alloSCT in intermediate and advanced stage AL patients. Prospective studies are required to prove whether serum Leptin could be used for guiding nutritional intervention in patients with AL undergoing alloSCT.
536 _ _ |a 313 - Krebsrisikofaktoren und Prävention (POF4-313)
|0 G:(DE-HGF)POF4-313
|c POF4-313
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a ALL
|2 Other
650 _ 7 |a AML
|2 Other
650 _ 7 |a Adiponectin
|2 Other
650 _ 7 |a acute lymphoblastic leukemia
|2 Other
650 _ 7 |a acute myeloid leukemia
|2 Other
650 _ 7 |a allogeneic stem cell transplantation
|2 Other
650 _ 7 |a body mass index
|2 Other
650 _ 7 |a leptin
|2 Other
650 _ 7 |a relapse
|2 Other
650 _ 7 |a survival
|2 Other
700 1 _ |a Dai, Hao
|0 P:(DE-He78)e1550b77d7eed3425c8e245362b45281
|b 1
700 1 _ |a Kordelas, Lambros
|0 0000-0003-3116-473X
|b 2
700 1 _ |a Beelen, Dietrich W
|b 3
700 1 _ |a Radujkovic, Aleksandar
|0 0000-0002-8543-5016
|b 4
700 1 _ |a Müller-Tidow, Carsten
|b 5
700 1 _ |a Dreger, Peter
|b 6
700 1 _ |a Luft, Thomas
|0 0000-0002-0387-1640
|b 7
773 _ _ |a 10.3390/ijms23042337
|g Vol. 23, no. 4, p. 2337 -
|0 PERI:(DE-600)2019364-6
|n 4
|p 2337
|t International journal of molecular sciences
|v 23
|y 2022
|x 1422-0067
909 C O |o oai:inrepo02.dkfz.de:179137
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)e1550b77d7eed3425c8e245362b45281
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-313
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Krebsrisikofaktoren und Prävention
|x 0
914 1 _ |y 2022
915 _ _ |a Creative Commons Attribution CC BY (No Version)
|0 LIC:(DE-HGF)CCBYNV
|2 V:(DE-HGF)
|b DOAJ
|d 2021-05-04
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-05-04
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-05-04
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2021-05-04
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2021-05-04
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2021-05-04
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2022-09-04T08:27:04Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2022-09-04T08:27:04Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Blind peer review
|d 2022-09-04T08:27:04Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2022-11-25
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2022-11-25
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b INT J MOL SCI : 2021
|d 2022-11-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2022-11-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2022-11-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2022-11-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2022-11-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1150
|2 StatID
|b Current Contents - Physical, Chemical and Earth Sciences
|d 2022-11-25
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b INT J MOL SCI : 2021
|d 2022-11-25
920 1 _ |0 I:(DE-He78)C020-20160331
|k C020
|l C020 Epidemiologie von Krebs
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C020-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21